Viracta Therapeutics closes NAVAL-1 trial and explores strategic options; Board of Directors initiates process to explore alternatives.

Unusual Whales
2025.02.07 20:16
On December 26, 2024, a company called Viracta Therapeutics, Inc. (Nasdaq: VIRX), located in San Diego, revealed plans to evaluate various strategic alternatives. This clinical-stage precision oncology firm specializes in handling virus-related cancers affecting patients globally. The Board of Directors is spearheading this initiative to explore multiple options for the company's future direction and growth.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.